Patents Examined by Noble Jarrell
  • 3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as RORgammaT inhibitors and uses thereof
    Patent number: 9487490
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: November 8, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kenneth J. Barr, John K. Maclean, Hongjun Zhang, Richard T. Beresis, Dongshan Zhang, Brian M. Andresen, Neville J. Anthony, Blair T. Lapointe, Nunzio Sciammetta
  • Chromene compound
    Patent number: 9487693
    Abstract: A chromene compound having a short fading half period, especially, a short fading half period even at a low temperature in a general-purpose polymer solid matrix. The chromene compound is represented by the following formula (1). wherein R1 is a hydroxyl group or the like, R2 and R3 are each an aryl group or the like, C* is a spiro carbon atom, a spiro ring A represented by the following formula is a saturated hydrocarbon ring having 4 to 12 ring member carbon atoms or the like, and at least one ring member carbon atom constituting the ring A is a group represented by the following formula (4), and X is a divalent group such as arylene group, wherein R7 and R8 are each a cycloalkyl group or the like.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: November 8, 2016
    Assignee: TOKUYAMA CORPORATION
    Inventors: Shinobu Izumi, Kazuhiro Teranishi, Yusuke Daikoku, Mitsuyoshi Sando
  • Methods for the treatment of pediatric otic disorders
    Patent number: 9486405
    Abstract: Disclosed herein are methods for the treatment of pediatric otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: November 8, 2016
    Assignee: OTONOMY, INC.
    Inventors: Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel
  • Small molecule inhibitors of Mcl-1 and the uses of thereof
    Patent number: 9486422
    Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having sulfonamido-1-hydroxynaphthalene structure which function as inhibitors of Mcl-1 protein, and their use as therapeutics for the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: November 8, 2016
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, WAYNE STATE UNIVERSITY
    Inventors: Zaneta Nikolovska-Coleska, Hollis D. Showalter, Chenzhong Liao, Ramzi Mohammad, Fardokht Abulwerdi
  • Azepino[4,5-B]indoles and methods of use
    Patent number: 9481676
    Abstract: This disclosure relates to new azepino[4,5-b]indole compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new 1,2,3,4,5,6-tetrahydroazepino[4,5-b]indoles. Pharmaceutical compositions are also provided.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: November 1, 2016
    Assignee: MEDIVATION TECHNOLOGIES, INC.
    Inventors: David T. Hung, Andrew Asher Protter, Rajendra Parasmal Jain, Sarvajit Chakravarty
  • Process for the preparation of tofacitinib and intermediates thereof
    Patent number: 9481679
    Abstract: The present invention provides compounds of Formula III and Formula VI, and processes for their preparation. The present invention further provides use of the compounds of Formula III and Formula VI for the preparation of tofacitinib or isomers or a mixture of isomers or salts thereof.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: November 1, 2016
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Mohammed Salman Hashmi, Yoginder Pal Sachdeva, Chandra Has Khanduri
  • Phosphonates with reduced toxicity for treatment of viral infections
    Patent number: 9475832
    Abstract: There are provided, inter alia, acyclic nucleoside phosphonate compounds having reduced toxicity and enhanced antiviral activity, and pharmaceutically accepted salts and solvates thereof. There are also provided methods of using the disclosed compounds for inhibiting viral RNA-dependent RNA polymerase, inhibiting viral reverse transcriptase, inhibiting replication of virus, including hepatitis C virus or a human retrovirus, and treating a subject infected with a virus, including hepatitis C virus or a human retrovirus.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: October 25, 2016
    Assignee: The Regents of the University of California
    Inventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
  • Antimicrobial agents
    Patent number: 9475783
    Abstract: The invention provides compounds of formula (I): wherein R1-R7 and W have any of the values defined in the specification, and salts thereof. The compounds have good solubility and are useful for treating bacterial infections.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: October 25, 2016
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Edmond J. LaVoie, Ajit Parhi, Yongzheng Zhang, Daniel S. Pilch, Malvika Kaul
  • Compounds and formulations suitable for radical scavenging
    Patent number: 9475810
    Abstract: The present invention relates to compositions and methods of using free radical scavengers with reduced 1O2 generation. In certain embodiments, these compositions and methods of use relate to fullerene-derived ketolactams and fullerene-derived ketolactam derivatives, fullerene derivatives, and/or fullerenes. In yet other embodiments, the invention relates to cosmetic or dermatological compositions comprising said free radical scavengers with reduced 1O2 generation.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: October 25, 2016
    Assignee: Solenne BV
    Inventors: David F. Kronholm, Alexander B. Sieval, Jan C. Hummelen
  • Preparation of bleaching catalysts
    Patent number: 9469666
    Abstract: The present invention concerns synthesizing manganese complexes in essentially non-aqueous solutions.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: October 18, 2016
    Assignee: Catexel Limited
    Inventors: Ronald Hage, Jianrong Zhang, Wei Zhao
  • Diallyl ethers of anhydrohexitols and processes for making the same
    Patent number: 9463448
    Abstract: The invention concerns diallylisoidide in a first aspect, and in a related aspect concerns an improved method for making the diallyl ether derivatives of anhydrohexitols generally, whether isosorbide, isomannide, isoidide or a mixture of two or all three of these, whereby these derivatives may be produced efficiently up to quantitative yields.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: October 11, 2016
    Assignee: Archer Daniels Midland Company
    Inventor: Kenneth Stensrud
  • Sulfonamide compounds and uses as TNAP inhibitors
    Patent number: 9458147
    Abstract: Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper-mineralization.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: October 4, 2016
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Anthony B. Pinkerton, Russell Dahl, Nicholas D. P. Cosford, Jose Luis Millan
  • Process for producing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid and complexes thereof
    Patent number: 9458117
    Abstract: A process for producing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) including salts and hydrates thereof of general formula (I) from the respective cyclen. The process involves the use of cationic- and anionic exchange resins and solvent treatments to remove the organic and inorganic contaminants. Any cations present in the raw DOTA or other contaminants resulting from the reaction of cyclen are largely reduced in early stages of the process allowing to obtain good yields of DOTA in a purified grade and in an easier and reliable way. The process is useful for the production of DOTA, of macrocyclic compounds including metal ions complexes thereof and of compositions including the macrocyclic compounds that can be used as contrast agents for magnetic resonance imaging.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: October 4, 2016
    Assignee: AGFA HEALTHCARE NV
    Inventors: Diederik Buffel, Rakesh Ganorkar, Jennifer Burt, Xavier Boi
  • Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta (G) quinazoline trisodium salt
    Patent number: 9458188
    Abstract: A new method for the synthesis of L-Glutamyl-?-D-Glutamic acid and its use in the synthesis of (2R)-((4S)-carboxy-4-(4,N-(((6S)-2-(hydroxymethyl)-4-oxo-3,4,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino)benzamido)butanamido)pentanedioic acid, 1 are provided. Also provided is an efficient method for the isolation and purification of the trisodium salt of the abovementioned acid, 2, in a form suitable for long term storage and use in a parenteral dosing form.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: October 4, 2016
    Assignee: BTG INTERNATIONAL LIMITED
    Inventors: James Alan Kerschen, Alexander James Bridges, Milind D. Choubal, Sean Mark Dalziel, Thomas Elliott Jacks, Andrew S. Thompson, James Robert Zeller
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 9458105
    Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: October 4, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Romyr Dominique, Francisco Javier Lopez-Tapia, Eric Mertz, Sung-Sau So
  • Paraffinic oil-in-water emulsions for controlling infection of crop plants by fungal pathogens
    Patent number: 9451773
    Abstract: This disclosure features fungicidal combinations that include a paraffinic oil and an emulsifier. The combinations can further include one or more of the following: pigments, silicone surfactants, anti-settling agents, conventional fungicides such as demethylation inhibitors (DMI) and quinone outside inhibitors (Qol) and water. The fungicidal combinations are used for controlling infection of a crop plant by a fungal pathogen.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: September 27, 2016
    Assignee: Suncor Energy Inc.
    Inventors: Michael Fefer, Jun Liu
  • Process for the preparation of calcobutrol
    Patent number: 9447053
    Abstract: A process for the preparation of the calcium complex of 10-(2, 3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclodecane-4,7-triacetic acid, also known as Calcobutrol, starting from the pure gadolinium complex (Gadobutrol) is disclosed. Also disclosed is Calcobutrol with a hitherto unknown level of purity.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: September 20, 2016
    Assignee: Bayer Intellectual Property GMBH
    Inventors: Johannes Platzek, Wilhelm Trentmann
  • DYRK1 inhibitors and uses thereof
    Patent number: 9446044
    Abstract: The present invention relates to novel thiazolo[5,4-f]quinazoline compounds and methods that are useful in the amelioration, treatment or control of Down's syndrome or early Alzheimer's disease or in the amelioration, treatment or control of cancers, especially solid tumors. More specifically, the invention relates to DYRK1A and/or DYRK1B inhibitors and to methods for preparing such compounds.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: September 20, 2016
    Assignee: DIAXONHIT
    Inventors: Bertrand Leblond, Anne-Sophie Casagrande, Laurent Desire, Alicia Foucourt, Thierry Besson
  • Derivatives of pyridinone as inhibitors for tissue transglutaminase
    Patent number: 9434763
    Abstract: The invention relates to pyridinone derivatives of general formula (I) as inhibitors of tissue transglutaminase, to methods for producing the pyridinone derivatives, to pharmaceutical compositions containing said pyridinone derivatives and to their use for the prophylaxis and treatment of diseases associated with tissue transglutaminase.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: September 6, 2016
    Assignee: ZEDIRA GMBH
    Inventors: Christian Buchold, Uwe Gerlach, Martin Hils, Ralf Pasternack, Johannes Weber
  • Pharmaceutical composition with improved bioavailability
    Patent number: 9427427
    Abstract: The invention relates to solid dispersions of poorly water soluble compounds, in particular Compound A as disclosed herein, formed by solvent co-precipitation or spray drying, resulting in improved bioavailability, safety and tolerability of said compounds.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: August 30, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Steve Lomuscio, Hua Ma, Michael Allen Matchett, Harpreet K. Sandhu, Navnit Hargovindas Shah, Yu-E Zhang